Harris L - Search Results

1

Phase II evaluation of thalidomide in patients with metastatic breast cancer.

Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF. Baidas SM, et al. Among authors: harris l. J Clin Oncol. 2000 Jul;18(14):2710-7. doi: 10.1200/JCO.2000.18.14.2710. J Clin Oncol. 2000. PMID: 10894870 Clinical Trial.

2

Can we increase survival in breast cancer with innovative applications of conventional drugs?

Swain SM, Harris LN. Swain SM, et al. Among authors: harris ln. Eur J Cancer. 1994;30A(4):423-4. doi: 10.1016/0959-8049(94)90409-x. Eur J Cancer. 1994. PMID: 8018395 No abstract available.

3

The role of primary chemotherapy in early breast cancer.

Harris L, Swain SM. Harris L, et al. Semin Oncol. 1996 Feb;23(1 Suppl 2):31-42. Semin Oncol. 1996. PMID: 8614843 Review.

4

Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.

Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, Hayes DF, Winer EP. Havlin KA, et al. Among authors: harris ln. Cancer Chemother Pharmacol. 1999;43(1):68-72. doi: 10.1007/s002800050864. Cancer Chemother Pharmacol. 1999. PMID: 9923543 Clinical Trial.

5

Phase I study of Doxil and vinorelbine in metastatic breast cancer.

Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Burstein HJ, et al. Among authors: harris ln. Ann Oncol. 1999 Sep;10(9):1113-6. doi: 10.1023/a:1008323200102. Ann Oncol. 1999. PMID: 10572612 Free article. Clinical Trial.

6

Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status.

Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst M, Greenberg C. Blackwell K, et al. Among authors: harris l. J Clin Oncol. 2000 Feb;18(3):600-8. doi: 10.1200/JCO.2000.18.3.600. J Clin Oncol. 2000. PMID: 10653875 Clinical Trial.

7

Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy.

Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB, Berry DA, Rizzeri D, Vredenburgh JJ, Bentley RC. Harris LN, et al. J Clin Oncol. 2001 Mar 15;19(6):1698-706. doi: 10.1200/JCO.2001.19.6.1698. J Clin Oncol. 2001. PMID: 11250999

8

First-line Herceptin monotherapy in metastatic breast cancer.

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. Vogel CL, et al. Among authors: harris ln. Oncology. 2001;61 Suppl 2:37-42. doi: 10.1159/000055400. Oncology. 2001. PMID: 11694786 Review.

9

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.

Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E; TLC D-99 Study Group. Harris L, et al. Cancer. 2002 Jan 1;94(1):25-36. doi: 10.1002/cncr.10201. Cancer. 2002. PMID: 11815957 Free article. Clinical Trial.

10

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Vogel CL, et al. Among authors: harris ln. J Clin Oncol. 2002 Feb 1;20(3):719-26. doi: 10.1200/JCO.2002.20.3.719. J Clin Oncol. 2002. PMID: 11821453 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,580 results

Search Page

Filters